Navigation Links
New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C
Date:12/3/2009

y Santaris Pharma A/S creates synthetically modified chemical versions of the normal nucleic acid building blocks of ribonucleic acids (RNA). These modified chemical versions called LNAs improve the drug-like qualities of resulting therapeutics (oligonucleotides) by improving affinity to their target RNA, boosting resistance to metabolism and improving tissue uptake. Upon systemic administration of these "naked" molecules, LNA-based therapeutics are delivered to many different tissues where they show potencies many-fold better than other oligonucleotide therapeutics.

About Santaris Pharma A/S

Santaris Pharma A/S is a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The Company's proprietary Locked Nucleic Acid (LNA) Drug Platform, in combination with its highly specialized and targeted drug development capabilities, offers potential partners pre-screened drug candidates for commercial consideration across a multitude of disease states. Santaris Pharma A/S research and development activities focus on infectious diseases and metabolic disorders while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, rare genetic disorders and inflammatory diseases. Santaris Pharma A/S, founded in 2003, is privately-held and headquartered in Denmark with operations in the US. As part of its broad patent estate, the Company holds exclusive worldwide rights to all therapeutic uses of LNAs. The Company has strategic partnerships with Enzon Pharmaceuticals, GlaxoSmithKline, Wyeth Pharmaceuticals (now part of Pfizer) and Shire plc. Please visit http://www.santaris.com for more information.

---------------------------------

    [1] World Health Organization -
'/>"/>
SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)...  Zacks.com announces the list of stocks featured in the ... the latest news and events impacting stocks and the financial ... BIIB - Free Report ), Gilead (Nasdaq: GILD ... Free Report ), AbbVie (NYSE: ABBV - Free Report ... Today, Zacks is promoting its ,Buy, stock recommendations. ...
(Date:7/31/2014)... AUSTIN, Texas , July 31, 2014 Vermillion, ... cancers and women,s health, will hold a conference call on ... discuss results for the second quarter ended June 30, 2014. ... to the call. Vermillion,s Chairman, President and CEO ... a question and answer period. Date: Thursday, August ...
(Date:7/31/2014)... TB Alliance, a not-for-profit with the ... affordable treatments, announced the appointment of Willo ... Mr. Brock comes to TB Alliance having most ... for WWF International (formerly known as the World ... guide the TB Alliance,s resource development, advocacy and ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2
... June 14, 2011 Orthopedics This Week announced today ... News to supply Orthopedics This Week, the #1 source ... terminal subscribers including some of the most prominent investors ... The Bloomberg network includes portfolio managers, central bankers, finance ...
... 2011 Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX ... the U.S. Food and Drug Administration (FDA) has extended ... for its review of the New Drug Application (NDA) ... The new PDUFA goal date is October 28, 2011. ...
Cached Medicine Technology:Orthopedics This Week Now on Bloomberg 2Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months 2Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months 3
(Date:7/31/2014)... York, NY (PRWEB) July 31, 2014 The VitalSleep ... the lower jaw forward to help open a snorers airway to ... anti-snoring remedy helped her relationship with her husband by ... am a 46 years old. My snoring began about 15 years ... my husband and children could not sleep and had to head ...
(Date:7/31/2014)... 2014 Today, Good Neighbor Pharmacy ... patient care by kicking off another year of ... first of many education sessions and initiatives took ... Good Neighbor Pharmacy and AmerisourceBergen’s annual conference. Sessions ... (CMS) Star Measures were a highlight and helped ...
(Date:7/31/2014)... Live To Be Sober , a ... guidance, advice and program information to people who want ... drug or alcohol addiction, proudly announced today that it ... country music’s bad boy, gone good. , "NBC's The ... commented Blake, whose new single Stomp (#Stomp; available on ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Clifton Dental ... the application of topical fluoride treatments to their adult ... and help with tooth sensitivity in patients that exhibit ... an infection that is commonly known as “tooth decay” ... tissues of the teeth. , Fluoride therapy ...
(Date:7/31/2014)... a novel method for creating self-assembled protein/polymer nanostructures ... cells. The work offers a promising new way ... engineering applications. The findings were published in the ... Edition . , "We have demonstrated that, by ... form completely new types of aggregates. These aggregates ...
Breaking Medicine News(10 mins):Health News:New Snoring Mouthpiece Reviews from VitalSleep 2Health News:Good Neighbor Pharmacy Reinforces Commitment to Helping Enhance Patient Care 2Health News:Good Neighbor Pharmacy Reinforces Commitment to Helping Enhance Patient Care 3Health News:Addiction Referral Service Live To Be Sober (LiveToBeSober.com) Announces Sponsorship of Jared Blake: Country Music’s Bad Boy, Gone Good 2Health News:Addiction Referral Service Live To Be Sober (LiveToBeSober.com) Announces Sponsorship of Jared Blake: Country Music’s Bad Boy, Gone Good 3Health News:NJ Top Dentists Approved, Clifton Dental Associates Now Actively Recommending the Application of Topical Fluoride Treatments to Adults 2Health News:Carnegie Mellon chemists create nanofibers using unprecedented new method 2
... Health Tax, is the Undisclosed Premium Surcharge that Pays for ... Join the Ranks of the Uninsured, the ,Hidden Health Tax, ... in 2009WASHINGTON, May 28 The so-called "hidden ... in 2008 according to a report released today by the ...
... PhD, is the winner of the third annual Liu Young ... providing support for a young scientist on the LA BioMed ... 2005 after receiving his PhD in microbiology, immunology and molecular ... and completing a postdoctoral fellowship in tumor immunology at UCLA ...
... 28 The UltraPulse CO2 fractional laser was featured ... exciting and revolutionary new treatment for scars. During the ... as infants told their personal story and discussed recent ... treatments with the groundbreaking ActiveFX and DeepFX technologies, the ...
... platform enables payors to compete like never before ... 28 HealthEdge, provider of the only modern, ... that it will be demonstrating the award-winning HealthRules ... conference in San Diego on June 3-5. ...
... 3 to 5 hours sleep per night, study shows, , , THURSDAY, ... is getting the recommended eight hours of sleep each night. ... of highly-caffeinated energy drinks, according to new research. , And, ... polled reported falling asleep in school at least twice ...
... service to journalists and other critical audiences around ... related news releases from participating companies issued via ... for this event.(Logo: http://www.newscom.com/cgi-bin/prnh/20090417/NY00642LOGO ... http://www.newscom.com/cgi-bin/prnh/20000306/PRNLOGO )The 45th American Society ...
Cached Medicine News:Health News:'Hidden Health Tax' for Family Health Care Coverage Climbed to $1,017 in 2008 2Health News:'Hidden Health Tax' for Family Health Care Coverage Climbed to $1,017 in 2008 3Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 2Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 3Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 4Health News:HealthEdge(R) to Demonstrate the Award-Winning HealthRules(R) Software Suite at AHIP Institute 2009 2Health News:Technology, Caffeine Keeping Teens Awake 2Health News:Technology, Caffeine Keeping Teens Awake 3Health News:2009 ASCO Annual Meeting and Conference News Distributed by PR Newswire Available at www.EventNewsCenter.com 2Health News:2009 ASCO Annual Meeting and Conference News Distributed by PR Newswire Available at www.EventNewsCenter.com 3
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
... Bench high, 26-31". Ergonomic design increases ... pnuematic control for easy height adjustment. ... allow easy mobility. Fixed footring standard. ... 5000 Volts to technical zero); ...
Inquire...
Medicine Products: